Next-generation antimicrobial therapies targeting resistant bacterial infections in humans
The World Health Organization has declared antimicrobial resistance one of the top 10 global public health threats facing humanity. Without effective antimicrobials, common infections become untreatable and routine medical procedures become high-risk.
Amphoraxe is developing novel antimicrobial peptides to address this urgent need, providing new therapeutic options where conventional antibiotics are failing.
Antimicrobial resistance is one of the greatest threats to modern medicine. As conventional antibiotics lose effectiveness, Amphoraxe is developing novel antimicrobial peptides that offer a new line of defense against resistant bacterial infections.
Our peptide candidates target drug-resistant pathogens through mechanisms that make it significantly harder for bacteria to develop resistance, providing a sustainable path forward for human therapeutics.
Interested in co-developing antimicrobial peptides for human health applications?
Get in Touch